Related Experiment Video

Updated: Sep 24, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
06:15

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

50.5K

Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary

Stephanie S Handler1, Nidhy P Varghese2, Erika B Rosenzweig3

  • 1Department of Pediatrics, Division of Cardiology Medical College of Wisconsin Milwaukee Wisconsin USA.

Pulmonary Circulation
|May 4, 2022
PubMed

Insights

Establishing optimal pediatric pulmonary hypertension (PH) programs requires a multidisciplinary team, accessible services, and dedicated education. This guide from the Pediatric Pulmonary Hypertension Network (PPHNet) aids program development and collaboration.

Area of Science:

  • Pediatric Cardiology and Pulmonology
  • Rare Disease Management
  • Healthcare Systems and Program Development

Background:

  • Pediatric pulmonary hypertension (PH) is a severe, life-threatening condition requiring specialized, multidisciplinary care.
  • Limited expert centers exist due to resource constraints and lack of program development knowledge.
  • The Pediatric Pulmonary Hypertension Network (PPHNet) comprises North American expert centers focused on advancing pediatric PH research and clinical care.

Purpose of the Study:

  • To identify and collectively outline key components for establishing and optimizing pediatric PH programs.
  • To provide a resource for newer or smaller programs to identify growth avenues and collaboration opportunities.
  • To share best practices in team composition, service access, and educational commitment for pediatric PH management.

Main Methods:

  • Querying member sites of the Pediatric Pulmonary Hypertension Network (PPHNet) for essential program components.
  • Discussing queried findings among expert centers to reach a consensus on optimal program elements.
  • Synthesizing collective insights into a structured overview of program development.

Main Results:

  • Key elements for optimal pediatric PH programs include specific team composition, guaranteed access to comprehensive services, and a strong commitment to ongoing education.
  • Consensus was reached on the critical factors for successful pediatric PH program development.
  • The findings highlight the importance of a structured approach to building expert PH centers.

Conclusions:

  • Optimal pediatric PH programs are built on a foundation of expert multidisciplinary teams, accessible specialized services, and robust educational initiatives.
  • This collective overview serves as a roadmap for developing and enhancing pediatric PH programs.
  • Collaboration and resource sharing are vital for advancing the care of children with PH.

Keywords:
program developmentpulmonary vascular diseaseregional care

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.3K
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.1K

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
302
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
267
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
333
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
234
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
55
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
264